Repros Therapeutics Inc.
Repros Therapeutics Inc. Announces That Proellex Shows No Adverse Cardiac Effects In a Pilot Trial
Published in Medical Verdicts and Law Weekly, May 29th, 2008
Repros Therapeutics Inc. (NasdaqGM:RPRX) released encouraging results from its pilot study of the potential for adverse cardiac events associated with administration of doses of Proellex up to four times higher than the intended marketed dose. The study was designed to assess the potential for QT prolongation, an indicator of potential adverse cardiac effects and a major safety consideration for the FDA.
Study Results
In preparation for conducting a thorough QT study (TQT), Repros has completed a pilot trial dosing healthy female volunteers for seven days with Proellex 200 mg. Formal QT studies are dosed for five days. This Proellex dose is 4 to 8...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- AARP New York
AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency - Ajamie Llp
Attorney Thomas R. Ajamie Named to Multi-Million Dollar Advocates Forum - Alliance for a Stronger Fda
FDA Commissioner Provides First-Ever 'Professional Judgment Letter' on FDA's Immediate Resource Needs - Alliance for Marriage
California High Court Decision Striking Down Marriage Underscores Need for Congress to Pass AFM's Marriage Protection Amendment - Allion Healthcare
Allion Healthcare Reports First Quarter 2008 Results - Alticor
UK Court Validates Amway Reforms - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
